Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results

PALO ALTO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and full year 2014 financial results and other information on Wednesday, March 11, 2015 at approximately 4:00 p.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call on Wednesday, March 11, 2015 at 4:30 p.m. Eastern Time.

To access the conference call via the Internet, go to www.ocerainc.com. To access the live conference call via phone, dial 877-317-6789. International callers may access the live call by dialing 412-317-6789. The reference name to enter the call is Ocera Therapeutics, Inc.

A replay of the call will be available for one month following the event. The replay of the conference call may be accessed on Wednesday, March 11, 2015 after 8:00 p.m. Eastern Time, via the Internet, at www.ocerainc.com, or via phone at 877-344-7529 for domestic callers, or 412-317-0088 for international callers. The reference number to enter the replay of the call is 10061684.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.

Susan Sharpe
Ocera Therapeutics, Inc.

Source:Ocera Therapeutics, Inc.